Every product company in regenerative medicine sells into a market the FDA and the FTC are reading. This enforcement watch for October 2026 reads what the agencies’ own pages show and turns it into seven lessons for manufacturers, distributors, and the clinics that buy from them. No recipient is named. The patterns are what matter, because the patterns are what repeat.
TLDR: The claim draws the letter, not the product. FDA pages show unapproved products sold with treatment claims, and FTC pages show that reviews and testimonials now sit under a rule with civil penalties. Your rep’s words and your deck end up in the clinic’s ads, so the clinic’s exposure can become yours too. This enforcement watch gives you seven lessons, the mistakes we see most, and a scenario, so you can fix pages before a letter rather than after.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
A lot of the practices and companies we work with have changed a page, a deck, or an ad this year because of a recent FDA or FTC action. None of them planned to. A letter landed somewhere in the industry, someone read it, and a sentence that had felt safe for years suddenly did not.
That is the useful thing about an enforcement watch. It tells you what the agencies are reading right now. You do not need the recipient’s name to learn the lesson. You need the product type, the claim type, and the agency.
This post gives you those patterns and seven lessons. I pulled the linked pages for this edition on October 2, 2026. Nothing here goes past what those pages say.
Why This Enforcement Watch Names Patterns, Not Companies
We do not call out companies by name in our content, even when the action is public. Plenty of clients have changed a page, a deck, or an ad because of a letter; the lesson gets published and the recipient does not. That is a standing rule at Regen Portal. It is also the more useful way to read enforcement.
A name tells you who got a letter. A pattern tells you whether you are next. The FDA’s own database says matters in a warning letter may have changed through later contact with the recipient, per the FDA warning letters database. So a letter is a snapshot of a claim on a date, not a verdict forever.
The database filters by issuing office, letter date, and subject. That is how I read it: by product type and claim type, never by name.
What the FDA Pages Show
The FDA pages show three patterns. Unapproved products get marketed with treatment claims. Products sold as section 361 tissue do not always meet the criteria. And “registered” gets presented as if it meant approved.
Start with the consumer alert. The FDA consumer alert on regenerative medicine, last updated in April 2024, says most such products are unapproved. It also says there are currently no FDA-approved exosome products. The FDA has approved a small number of cell-based products, each only for a specific labeled use. The same page lists conditions these products get marketed for without approval, from orthopedic conditions to chronic pain.
That is pattern one. A product with no approval, sold with a sentence that names a disease or an outcome. The sentence is the problem, not the product.
Pattern two sits in the tissue rules. A cell or tissue product stays under section 361 only if it meets every criterion in the FDA’s HCT/P regulations, including minimal manipulation and homologous use. When the advertising describes a use the tissue does not perform in the body, the product may no longer fit. Counsel decides that for any one product. The pattern is that the marketing opened the question.
Pattern three is the word “registered.” Tissue establishments must register with the FDA and list their products. Registration is a filing, not a review or an approval. “FDA registered clinic” is the credential claim we see most often on regen sites. When a filing gets dressed up as a stamp, it reads as an approval claim.
The 2026 letters in the FDA database fit those patterns, and one adds to them. In August 2026, the FDA’s biologics center sent a warning letter over umbilical cord and exosome products. The letter quoted claims about arthritis and inflammation, and cell counts per vial.
In September 2026, the same center sent a warning letter over a cord blood cell product. That letter quoted no cure claim. It quoted mechanism language from the website and hedged lines from a white paper. Also in September 2026, the FDA’s drug center wrote to a compounding pharmacy. It said GLP-1 drugs compounded with an added vitamin appeared to be copies of approved drugs.
Now put the FTC side next to it, because the same pages get read by two agencies.
What the FTC Adds on Claims and Reviews
The FTC adds two things. Health claims need competent and reliable scientific evidence before they run. And reviews and testimonials now sit under a rule that carries civil penalties.
The Consumer Reviews and Testimonials Rule went into effect on October 21, 2024, per the FTC’s rule Q&A. It covers fake or false reviews and testimonials, paying for a particular sentiment, undisclosed insider reviews, and suppressing reviews through threats. Incentives are allowed as long as there is no express or implied requirement that the review say something in particular. Google’s review policies are stricter and do not allow rewards for reviews at all. The Q&A also says courts may impose civil penalties for knowing violations.
In December 2025, the FTC published a business blog post about warning letters it sent under that rule. The letters alerted companies to potential violations involving fake reviews and incentives tied to five-star ratings, per the FTC’s December 2025 post. The post says those practices misrepresent consumer experiences and warns that civil penalties add up per violation. I will not name the recipients.
In July 2026, the FTC approved a final order in a supplement case that joined both issues. The complaint cited reviews written by employees and vendors, and reviews bought with a free product or a price break for five stars. It also cited health claims with no competent evidence behind them. The order carried a $4 million judgment, per the FTC’s press release.
On the claims side, the FTC’s Health Products Compliance Guidance holds every party that takes part in marketing responsible. It names distributors and retailers alongside marketers. It judges the net impression of the whole message, not the literal words.
Those are the agency patterns; the seven lessons turn them into work for your company.
Enforcement Watch Lessons 1 to 4: The Claim Is the Exposure
The first four lessons share one idea. Agencies read claims, and claims travel. Your product’s status is fixed; the sentences around it are not.
Lesson 1: the claim, not the product, draws the letter. The consumer alert does not say cells and tissue are bad. It says unapproved products are marketed for conditions with no approval. Take the disease name and the outcome off the page and the exposure drops. It does not vanish. The September 2026 letter rested on mechanism language and a white paper, with no cure claim on the page. Keep them, and the product’s paperwork will not save it.
Lesson 2: your rep’s words are your claims. Reps routinely say things to clinic owners that are not FDA compliant, and the industry treats that as normal. We have watched that language travel from the rep’s pitch into the clinic’s own ads, sometimes word for word, “best thing since sliced bread” included. Spoken does not mean safe. Our rules for biologics reps show how to give reps a written claim sheet.
Lesson 3: the clinic’s ad is downstream of your deck. The clinic did not invent the phrase in its Facebook ad. It copied it from slide four. When a letter cites a clinic page, your product may be named on that page. Now your product sits in a public record next to a claim you never approved. Read what FDA warning letters mean for the clinics you sell to. Their letter can become your problem too.
Lesson 4: reviews and testimonials are now a rule with penalties. The rule has been in effect since October 2024, and the December 2025 letters show the FTC is using it. A clinic that offers a gift for a five-star review is inside the rule. A product company that posts a paid doctor’s testimonial without saying so has a separate problem under the FTC Endorsement Guides and Section 5 of the FTC Act. Our post on reviews without rule violations covers the clinic side.
Lessons five to seven are about what to do on Monday.
Lessons 5 to 7: Fix the Page, Then Prove You Did
The last three lessons are operational. Stop using the word that reads as approval, fix pages before a letter, and keep a record of every change.
Lesson 5: “registered” is a red flag word. Say it only as a fact, with the filing next to it. Never as a badge, never in a headline, never with “so you are covered” after it. Registration means the agency knows you exist. Nothing more.
Lesson 6: fix the page before the letter, not after. Every company we have seen change a page after an action could have changed it the month before. The pattern was already public. Our compliance review service starts with claims, because that is where the exposure sits. Then reviews and testimonials, then patient data, then the record.
Lesson 7: document what changed and when. A letter asks what you knew and when you acted. A dated change log answers it. Record the page, the old sentence, the new sentence, the reason, and the date. If an AI tool drafted the copy, record that too. Our post on AI-drafted marketing copy explains why the tool never carries the liability.
The table below puts the FDA and FTC patterns from this enforcement watch in one place. The third column is the lesson that fits each.
| Pattern | Who reads it | Lesson that fits |
|---|---|---|
| Unapproved product with a disease or outcome claim | FDA | Lesson 1 |
| Tissue marketed for a use outside the 361 criteria | FDA | Lessons 2 and 3 |
| “Registered” presented as approval | FDA and FTC | Lesson 5 |
| Fake, paid, or filtered reviews and testimonials | FTC | Lesson 4 |
| Health claim with no competent evidence behind it | FTC | Lessons 6 and 7 |
Five patterns, seven lessons, and most companies trip on the same handful of mistakes.
Common Mistakes When Reading an Enforcement Watch
The mistakes we see most are reading mistakes, not legal ones. A company reads a letter as a story about someone else, then keeps the same sentence on its own site.
The first mistake is reading the recipient instead of the pattern. A company sees a letter about a different product category and relaxes. The claim type was the same.
The second mistake is assuming a 361 product may be marketed any way you like. The 361 status depends on the criteria, and homologous use is one of them. Marketing that describes a different use can be the fact that opens the question.
The third mistake is treating testimonials as different from reviews. The FTC Q&A says the rule’s provisions on what reviews say apply in a similar way to testimonials. A paid physician quote on your product page is a testimonial, and the reader needs to know it is paid.
The fourth mistake is fixing the website and forgetting everything else. The deck, the one-pager, the rep’s email template, and the trade show banner all carry the same claim. A letter can cite any of them. The scenario below shows how those mistakes stack up in one company.
Picture a Product Company That Read the Pattern Late
Picture a distributor that carries an amniotic product regulated as a section 361 HCT/P. It sells into pain practices in several states. Its deck has a slide that says the product helps patients avoid surgery. Its reps repeat the line on every visit.
Two of its clinic accounts now have that line on a service page with the product name under it. One clinic collected its testimonials with a gift card offer that mentioned “five stars.” The other posted an “FDA registered” badge on its homepage. Nobody at the distributor has seen either page.
Trace the exposure. The slide is an outcome claim for an unapproved use. The service pages tie the product to that claim in public. The testimonials are inside the FTC rule. The badge reads as an approval claim. Four problems, none of them on the distributor’s own website.
Now picture the same company after reading this enforcement watch. It pulls the slide and rewrites the deck with counsel. It sends every account a one-page claim sheet. It asks the two clinics to drop the gift card language and the badge, and offers a compliant review request script instead. It logs every change with a date.
Whether a letter ever arrives is not in the company’s control. What the agency would find is.
Frequently Asked Questions
What Is an Enforcement Watch?
An enforcement watch is a dated read of what the FDA and the FTC have published about marketing conduct in an industry. It sorts the actions by product type and claim type and turns them into lessons. It never needs a recipient’s name. The pattern is what a company can act on.
Does a Warning Letter Mean a Company Broke the Law?
Not by itself. The FTC’s December 2025 post describes its letters as alerts about potential violations. The FDA’s database notes that matters in a letter may have changed after later contact with the recipient. A letter is a snapshot of a claim on a date. What it means for any one company is a question for counsel.
Can We Still Ask Customers for Reviews?
Yes. The FTC Q&A says the rule does not prohibit incentives for reviews, as long as there is no express or implied requirement that the review say something particular. Asking is fine. Google’s review policies do not allow rewards for reviews at all, so ask and offer nothing. Paying for five stars is not allowed. Filtering out the bad ones is not. Posting a testimonial from someone you pay without saying so is not.
Is “FDA Registered” an Illegal Claim?
The fact of registration is a fact. The problem is the net impression. If “FDA registered” sits in a headline or a badge, a reader takes it as approval, and no 361 product has one. State it plainly, with the listing next to it, or leave it off. Whether a page crosses the line is a question for counsel.
How Often Should We Run an Enforcement Watch?
Quarterly is a workable rhythm for most product companies. Read the FDA database by product type and subject, read the FTC business blog, and compare each new pattern against your deck, website, and rep templates. Log what you changed. If a pattern lands close to your product, do not wait.
Key Takeaways
- The claim draws the letter, not the product, so the disease name and the outcome come off first. Mechanism language, cell counts, and white papers come off next.
- The FDA’s consumer alert says most of these products are unapproved and no exosome product is approved.
- A rep’s spoken pitch is a claim, and it travels into the clinic’s ads, sometimes word for word.
- Reviews and testimonials sit under an FTC rule with civil penalties, and the December 2025 letters show it is in use.
- “Registered” is a filing, not a badge, and it never belongs where a reader would take it as approval.
- Fix the deck, the one-pager, and the rep templates along with the website, then log every change with a date.
- Run an enforcement watch by pattern, on a schedule, and let counsel decide how each pattern applies to your product.
Your Next Step
An enforcement watch is only useful if someone compares it against your materials. We do that work for manufacturers and distributors, alongside your counsel, across the deck, the product page, the rep templates, and the review process.
Regen Portal sees both the supplier and the clinic side of this conversation, which is why the fixes tend to hold.
PS: Send us the deck, page, or ad you are least sure about and we will run a free compliance audit on it.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
